Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature
ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diag...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2016-01, Vol.9, p.4301-4305 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4305 |
|---|---|
| container_issue | |
| container_start_page | 4301 |
| container_title | OncoTargets and therapy |
| container_volume | 9 |
| creator | Zhu, You-Cai Xu, Chun-Wei Ye, Xiao-Qian Yin, Man-Xiang Zhang, Jin-Xian Du, Kai-Qi Zhang, Zhi-Hao Hu, Jian |
| description | ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation. |
| doi_str_mv | 10.2147/OTT.S109415 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4956058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A500289312</galeid><sourcerecordid>A500289312</sourcerecordid><originalsourceid>FETCH-LOGICAL-c572t-dd9dbae295634072be901cc9ba7b17684d883b6e32c333f9ac54f05c973877b03</originalsourceid><addsrcrecordid>eNqNkt9rFDEQxxdRbK0--S4BwRe5Mz92N4kPhVLaKhwctOdzyGZnb1N2kzPJtvjfm9qzdwdCJQ8Jk898Z5j5FsV7gueUlPzLcrWa3xAsS1K9KI4J4WJWS4Zf7r2Pijcx3mJc14KWr4sjyktRM0aPi2ExuTUy2hkI6N6mHhnvzBQCuIQuri6v0Tglnax3SLsWXS9vCAqgQ9BuDWOGviKd0yPk6MaH9IcKcGfhHvkOpR7QYBMEnaYAb4tXnR4ivNveJ8WPy4vV-bfZYnn1_fxsMTMVp2nWtrJtNFBZ1azEnDYgMTFGNpo3hNeibIVgTQ2MGsZYJ7Wpyg5XRnImOG8wOylOH3U3UzNCa3KbQQ9qE-yowy_ltVWHP872au3vVJlL4kpkgY9bgeB_ThCTuvVTcLlnRWkpSlZLwnbUWg-grOt8FjOjjUadVZhRyUldPUNhKiQjNFPzf1D5tDDavBLobI4fyP5nwq7Cp72EHvSQ-uiH6WG38VD5GXCn-PkRNMHHGKB7mjDB6sGaKltTba2Z6Q_7S3li_3qR_QaRR9qU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2248436913</pqid></control><display><type>article</type><title>Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature</title><source>Dove Press Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>PubMed Central</source><creator>Zhu, You-Cai ; Xu, Chun-Wei ; Ye, Xiao-Qian ; Yin, Man-Xiang ; Zhang, Jin-Xian ; Du, Kai-Qi ; Zhang, Zhi-Hao ; Hu, Jian</creator><creatorcontrib>Zhu, You-Cai ; Xu, Chun-Wei ; Ye, Xiao-Qian ; Yin, Man-Xiang ; Zhang, Jin-Xian ; Du, Kai-Qi ; Zhang, Zhi-Hao ; Hu, Jian</creatorcontrib><description>ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S109415</identifier><identifier>PMID: 27486332</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Abbreviations ; Adenocarcinoma ; Cancer therapies ; Care and treatment ; Case Report ; Case reports ; Chemotherapy ; Development and progression ; Epidermal growth factor ; Family medical history ; Gene mutations ; Genes ; Genetic aspects ; Health aspects ; Kinases ; Laboratories ; Lung cancer ; Lung cancer, Non-small cell ; Medical imaging ; Mutation ; Pathology ; Patients ; Polymerase chain reaction ; Surgery ; Thoracic surgery ; Thyroid gland ; Tumors</subject><ispartof>OncoTargets and therapy, 2016-01, Vol.9, p.4301-4305</ispartof><rights>COPYRIGHT 2016 Dove Medical Press Limited</rights><rights>2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Zhu et al. This work is published and licensed by Dove Medical Press Limited 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c572t-dd9dbae295634072be901cc9ba7b17684d883b6e32c333f9ac54f05c973877b03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956058/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956058/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27486332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, You-Cai</creatorcontrib><creatorcontrib>Xu, Chun-Wei</creatorcontrib><creatorcontrib>Ye, Xiao-Qian</creatorcontrib><creatorcontrib>Yin, Man-Xiang</creatorcontrib><creatorcontrib>Zhang, Jin-Xian</creatorcontrib><creatorcontrib>Du, Kai-Qi</creatorcontrib><creatorcontrib>Zhang, Zhi-Hao</creatorcontrib><creatorcontrib>Hu, Jian</creatorcontrib><title>Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation.</description><subject>Abbreviations</subject><subject>Adenocarcinoma</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Epidermal growth factor</subject><subject>Family medical history</subject><subject>Gene mutations</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Medical imaging</subject><subject>Mutation</subject><subject>Pathology</subject><subject>Patients</subject><subject>Polymerase chain reaction</subject><subject>Surgery</subject><subject>Thoracic surgery</subject><subject>Thyroid gland</subject><subject>Tumors</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkt9rFDEQxxdRbK0--S4BwRe5Mz92N4kPhVLaKhwctOdzyGZnb1N2kzPJtvjfm9qzdwdCJQ8Jk898Z5j5FsV7gueUlPzLcrWa3xAsS1K9KI4J4WJWS4Zf7r2Pijcx3mJc14KWr4sjyktRM0aPi2ExuTUy2hkI6N6mHhnvzBQCuIQuri6v0Tglnax3SLsWXS9vCAqgQ9BuDWOGviKd0yPk6MaH9IcKcGfhHvkOpR7QYBMEnaYAb4tXnR4ivNveJ8WPy4vV-bfZYnn1_fxsMTMVp2nWtrJtNFBZ1azEnDYgMTFGNpo3hNeibIVgTQ2MGsZYJ7Wpyg5XRnImOG8wOylOH3U3UzNCa3KbQQ9qE-yowy_ltVWHP872au3vVJlL4kpkgY9bgeB_ThCTuvVTcLlnRWkpSlZLwnbUWg-grOt8FjOjjUadVZhRyUldPUNhKiQjNFPzf1D5tDDavBLobI4fyP5nwq7Cp72EHvSQ-uiH6WG38VD5GXCn-PkRNMHHGKB7mjDB6sGaKltTba2Z6Q_7S3li_3qR_QaRR9qU</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Zhu, You-Cai</creator><creator>Xu, Chun-Wei</creator><creator>Ye, Xiao-Qian</creator><creator>Yin, Man-Xiang</creator><creator>Zhang, Jin-Xian</creator><creator>Du, Kai-Qi</creator><creator>Zhang, Zhi-Hao</creator><creator>Hu, Jian</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature</title><author>Zhu, You-Cai ; Xu, Chun-Wei ; Ye, Xiao-Qian ; Yin, Man-Xiang ; Zhang, Jin-Xian ; Du, Kai-Qi ; Zhang, Zhi-Hao ; Hu, Jian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c572t-dd9dbae295634072be901cc9ba7b17684d883b6e32c333f9ac54f05c973877b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Abbreviations</topic><topic>Adenocarcinoma</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Epidermal growth factor</topic><topic>Family medical history</topic><topic>Gene mutations</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Medical imaging</topic><topic>Mutation</topic><topic>Pathology</topic><topic>Patients</topic><topic>Polymerase chain reaction</topic><topic>Surgery</topic><topic>Thoracic surgery</topic><topic>Thyroid gland</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, You-Cai</creatorcontrib><creatorcontrib>Xu, Chun-Wei</creatorcontrib><creatorcontrib>Ye, Xiao-Qian</creatorcontrib><creatorcontrib>Yin, Man-Xiang</creatorcontrib><creatorcontrib>Zhang, Jin-Xian</creatorcontrib><creatorcontrib>Du, Kai-Qi</creatorcontrib><creatorcontrib>Zhang, Zhi-Hao</creatorcontrib><creatorcontrib>Hu, Jian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, You-Cai</au><au>Xu, Chun-Wei</au><au>Ye, Xiao-Qian</au><au>Yin, Man-Xiang</au><au>Zhang, Jin-Xian</au><au>Du, Kai-Qi</au><au>Zhang, Zhi-Hao</au><au>Hu, Jian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>9</volume><spage>4301</spage><epage>4305</epage><pages>4301-4305</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>27486332</pmid><doi>10.2147/OTT.S109415</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2016-01, Vol.9, p.4301-4305 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4956058 |
| source | Dove Press Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); PubMed Central |
| subjects | Abbreviations Adenocarcinoma Cancer therapies Care and treatment Case Report Case reports Chemotherapy Development and progression Epidermal growth factor Family medical history Gene mutations Genes Genetic aspects Health aspects Kinases Laboratories Lung cancer Lung cancer, Non-small cell Medical imaging Mutation Pathology Patients Polymerase chain reaction Surgery Thoracic surgery Thyroid gland Tumors |
| title | Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T09%3A08%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lung%20cancer%20with%20concurrent%20EGFR%20mutation%20and%20ROS1%20rearrangement:%20a%20case%20report%20and%20review%20of%20the%20literature&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Zhu,%20You-Cai&rft.date=2016-01-01&rft.volume=9&rft.spage=4301&rft.epage=4305&rft.pages=4301-4305&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S109415&rft_dat=%3Cgale_pubme%3EA500289312%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2248436913&rft_id=info:pmid/27486332&rft_galeid=A500289312&rfr_iscdi=true |